



## Article

# The First Phytochemical Investigation of *Artemisia divaricate*: Sesquiterpenes and Their Anti-Inflammatory Activity

 Siqi Yan <sup>1,2,3</sup>, Changqiang Ke <sup>1,2</sup>, Zheling Feng <sup>1,2</sup>, Chunping Tang <sup>1,2,\*</sup>  and Yang Ye <sup>1,2,3,4,\*</sup> 

<sup>1</sup> State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; s20-yansiqi@simm.ac.cn (S.Y.); kechangqiang@simm.ac.cn (C.K.); fengzheling@simm.ac.cn (Z.F.)

<sup>2</sup> Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

<sup>3</sup> University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China

<sup>4</sup> School of Life Science and Technology, ShanghaiTech University, Shanghai 201203, China

\* Correspondence: tangcp@simm.ac.cn (C.T.); yye@simm.ac.cn (Y.Y.)

**Abstract:** *Artemisia divaricate* belongs to the *Artemisia* genus of the family of Compositae, a sort of perennial herb endemic in most regions of China. For the first time, a phytochemical investigation was carried out on the whole plant of *Artemisia divaricate*, resulting in the identification of 39 sesquiterpenes, with 9 of them being new (1–9). The structures of the new compounds were fully established using extensive analysis of MS and 1D and 2D NMR spectroscopic data and density functional theory (DFT) NMR calculations. Their structures involve germacrane, eudesmane, and bisabolane types. All the new isolates were evaluated for their anti-inflammatory activities in lipopolysaccharide (LPS)-stimulated murine macrophages of RAW 264.7 cells. Compounds **2** and **8** showed a significant inhibition effect on NO production, with IC<sub>50</sub> values of 5.35 ± 0.75 and 7.68 ± 0.54 μM, respectively.

**Keywords:** *Artemisia divaricate*; sesquiterpene; divaricanolide A–I; anti-inflammatory activity



**Citation:** Yan, S.; Ke, C.; Feng, Z.;

Tang, C.; Ye, Y. The First

Phytochemical Investigation of *Artemisia divaricate*: Sesquiterpenes and Their Anti-Inflammatory Activity. *Molecules* **2023**, *28*, 4254. <https://doi.org/10.3390/molecules28104254>

Academic Editors: Piotr P. Wiczorek and Katarzyna Pokajewicz

Received: 10 April 2023

Revised: 18 May 2023

Accepted: 19 May 2023

Published: 22 May 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


## 1. Introduction

Natural products, defined as components or metabolites of animals, plants, or microorganisms, play a highly important role in drug discovery and development due to their diversified structures and bioactivities [1]. Sesquiterpenes, which are an essential class of secondary metabolites, have a wide distribution in plants, especially those of the Asteraceae family [2]. The *Artemisia* genus, one of the largest genera of the Asteraceae family, possesses a unique position in traditional Chinese medicine, as a variety of *Artemisia* plants has a long history of being used as a medicine [3]. Extensively, phytochemical investigations on *Artemisia* plants have been launched for decades, yielding numerous sesquiterpenoid compounds, including mainly eudesmanolides, guaianolides, and germacranolides [4–7]. It is noteworthy that germacranolides exist as the largest group, which act as biogenetic precursors for the other types of sesquiterpene lactones. Previous investigations revealed the diversity of the pharmacological properties of germacranolides, such as antitumor [8], anti-inflammatory [9], antibacterial [10], cytotoxic [11], and immune [12] effects.

*Artemisia divaricate* (Pamp.) Pamp., a species endemic in China, is a perennial herbaceous plant mainly distributed in western Hubei, western Sichuan, and northern Yunnan [13]. So far, no phytochemical investigations have been reported on this plant.

In our continuous effort to search for bioactive constituents from natural sources, a systematic investigation of *A. divaricate* was performed, resulting in the isolation of 39 sesquiterpenes from the title plant for the first time. Herein, we describe the isolation and structural elucidation of nine undescribed sesquiterpenes of eudesmane or germacrane types (Figure 1; structures of known compounds, see Figure S1 in Supporting Information). Their structures were elucidated using extensive analysis of the spectroscopic data and

DFT NMR calculations. All the new isolates were evaluated for their anti-inflammatory activities in lipopolysaccharide (LPS)-stimulated murine macrophages of RAW 264.7 cells, and two compounds (**2** and **8**) showed a significant inhibitory effect on NO production.



**Figure 1.** Structures of new compounds 1–9.

## 2. Results and Discussion

### 2.1. Structural Elucidation

Compound **1**, the obtained white powder, had a molecular formula of  $C_{19}H_{28}O_6$ , which was established using the HR-ESIMS ion at  $m/z$  375.1858  $[M + Na]^+$  (calcd. for  $C_{19}H_{28}O_6Na$ , 375.1784), suggesting the presence of six degrees of unsaturation. The IR showed absorption bands for hydroxy ( $3440\text{ cm}^{-1}$ ) and carbonyl groups ( $1715$  and  $1626\text{ cm}^{-1}$ ). In the  $^1H$  and  $^{13}C$  NMR spectra of **1** (Tables 1 and 2), signals for a 15-carbon skeleton, two substitution groups of an ethoxy group [ $\delta_H$  4.25 (2H, q),  $\delta_C$  61.2;  $\delta_H$  1.33 (3H, t),  $\delta_C$  14.3], and an acetoxy group [ $\delta_H$  1.95 (3H, s);  $\delta_C$  170.3, 21.2] were observed. The skeletal carbons were ascribed to a tertiary methyl [ $\delta_H$  0.94 (3H, s),  $\delta_C$  24.2], a vinylic methyl [ $\delta_H$  1.86 (3H, s),  $\delta_C$  11.5], three oxygenated methine [ $\delta_H$  3.61 (dd),  $\delta_C$  75.6;  $\delta_H$  4.03 (dd),  $\delta_C$  71.3;  $\delta_H$  5.41 (ddd),  $\delta_C$  70.0], trisubstituted double bonds [ $\delta_H$  5.34 (dd);  $\delta_C$  122.1, 134.5], an exocyclic double bond [ $\delta_H$  5.73 (s), 6.35 (s);  $\delta_C$  128.9, 138.6], and an ester carbonyl group ( $\delta_C$  167.0), which suggested an eudesmane-type structure of **1**. In the  $^1H$ - $^1H$  COSY spectrum, two fragments of H-1/H<sub>2</sub>-2/H-3 and H-5/H-6/H-7/H-8/H<sub>2</sub>-9 were established (Figure 2). The HMBC correlations from one methyl ( $\delta_H$  1.86) to C-3 ( $\delta_C$  122.1), C-4 ( $\delta_C$  134.5), and C-5 ( $\delta_C$  52.0) and from the other methyl ( $\delta_H$  0.94) to C-1 ( $\delta_C$  75.6), C-5 ( $\delta_C$  52.0), C-9 ( $\delta_C$  40.2), and C-10 ( $\delta_C$  38.9) further presented a nucleus moiety of two fused six-membered rings, with a hydroxyl group attached to C-1. The HMBC correlations from H<sub>2</sub>-13 ( $\delta_H$  6.35, 5.73) to C-7 ( $\delta_C$  57.2), C-11 ( $\delta_C$  138.6), and C-12 ( $\delta_C$  167.0) indicated an acrylic acid was placed at C-7 (Figure 2). The ethoxy group was confirmed to be a part of an ethyl ester group from the HMBC correlation between the oxygenated methylene and C-12 ( $\delta_C$  167.0). However, the location of the acetoxy group remained unclear due to the absence of a key HMBC correlation relevant to H-8 ( $\delta_H$  5.41, ddd).

Based on the HR-ESIMS data, compound **2** (white powder) was designated a molecular formula of  $C_{19}H_{28}O_6$ , the same as that of **1**. The IR showed absorption bands for hydroxy ( $3440\text{ cm}^{-1}$ ) and carbonyl groups ( $1715$  and  $1626\text{ cm}^{-1}$ ). A detailed NMR analysis of compound **2** (Tables 1 and 2) showed high similarities between these two compounds, suggesting they might share the same planar structure. Detailed analysis of its  $^1H$ - $^1H$  COSY and HMBC data further supported such elucidation (Figure 2).

**Table 1.**  $^{13}\text{C}$  NMR data of compounds 1–9 ( $\delta$  in ppm, measured in  $\text{CDCl}_3$ ).


No.	1	2	3	4	5	6	7	8	9
1	75.6	73.3	78.5	41.2	40.9	67.7	76.2	76.2	37.3
2	32.8	32.3	31.8	24.8	24.8	29.8	27.8	27.8	23.7
3	122.1	120.1	34.9	123.4	132.3	22.7	38.0	38.0	77.7
4	134.5	134.7	144.6	127.2	127.3	150.0	74.0	73.7	144.5
5	52.0	45.3	54.8	45.4	45.3	74.6	138.0	138.0	41.9
6	71.3	71.5	68.5	77.4	76.7	31.2	130.9	130.9	81.8
7	57.2	57.6	54.8	55.8	58.8	42.2	52.0	52.0	49.7
8	70.0	70.3	69.6	132.5	125.0	28.7	31.6	31.6	73.9
9	40.2	39.3	41.9	147.1	145.1	128.4	30.5	30.5	77.1
10	38.9	38.7	41.1	73.0	72.9	136.0	150.3	151.4	69.8
11	138.6	138.6	138.5	139.6	42.2	147.1	148.0	148.0	138.7
12	167.0	166.9	166.9	170.6	178.1	23.5	21.5	21.5	168.8
13	128.9	128.8	128.2	121.1	12.6	110.5	109.3	109.3	120.6
14	24.2	24.8	12.4	23.3	23.3	16.5	110.6	110.5	20.6
15	11.5	14.3	109.1	17.8	17.8	113.0	29.3	29.3	118.2
OAc	170.3	170.5	170.3						173.0
	21.2	21.2	21.2						20.6
1'	61.2	61.3	61.1						
2'	14.3	17.6	14.3						

**Table 2.**  $^1\text{H}$  NMR data of compounds 1–5 ( $\delta$  in ppm,  $J$  in Hz, measured in  $\text{CDCl}_3$ ).

No	1	2	3	4	5
1	3.61 (dd, 10.1, 7.1)	3.40–3.36 (m)	3.47 (dd, 11.6, 4.7)	1.72 (2H, m)	1.74–1.68 (2H, m)
2	2.36–2.45 (m) 1.90 (overlapped)	2.46 (overlapped) 2.02 (ddd, 10.5, 4.5, 2.2)	1.88 (m) 1.58 (overlapped)	2.27 (m) 2.17 (m)	2.25 (m) 2.17–2.11 (m)
3	5.34 (dd, 4.2, 2.3)	5.30 (dd, 4.5, 2.2)	2.36 (ddd, 13.6, 6.4, 3.7) 2.09 (ddd, 14.9, 13.6, 5.3)	5.18 (dd, 8.2, 8.1)	5.10 (dd, 11.1, 2.1)
5	1.97 (overlapped)	2.26 (d, 10.9)	1.83 (d, 10.4)	2.77 (dd, 12.2, 2.9) 2.61 (dd, 12.2, 12.2)	2.73 (dd, 12.1, 2.9) 2.49 (dd, 12.1, 9.9)
6	4.03 (dd, 11.4, 10.4)	4.07 (dd, 10.9, 10.5)	4.23 (dd, 10.4, 10.4)	3.97 (ddd, 12.2, 9.8, 2.9)	3.99 (ddd, 12.1, 9.9, 2.9)
7	2.50 (dd, 11.7, 10.4)	2.50 (dd, 11.4, 10.5)	2.62 (dd, 11.3, 10.4)	3.57 (dd, 9.8, 8.8)	2.62 (dd, 12.1, 9.5)
8	5.41 (ddd, 11.7, 11.1, 4.8)	5.43 (ddd, 11.8, 11.4, 5.2)	5.33 (ddd, 11.3, 11.2, 4.6)	5.15 (dd, 16.1, 8.8)	5.16 (dd, 16.0, 9.5)
9	2.32 (dd, 12.2, 4.8) 1.19 (dd, 12.2, 11.1)	1.88 (dd, 12.2, 11.8) 1.65 (dd, 12.2, 5.2)	2.34–2.31 (m) 1.29 (dd, 11.2, 4.9)	5.71 (d, 16.1)	5.60 (d, 16.0)
11					2.43 (dq, 12.1, 6.9)
12					
13	6.35 (s) 5.73 (s)	6.34 (d, 1.2) 5.72 (d, 1.2)	6.33 (d, 1.1) 5.71 (d, 1.1)	6.17 (d, 3.3) 5.46 (d, 3.3)	1.19 (3H, d, 6.9)
14	0.94 (3H, s)	0.94 (3H, s)	0.88 (3H, s)	1.39 (3H, s)	1.37 (3H, s)
15	1.86 (3H, s)	1.91 (3H, br s)	5.03 (d, 1.6) 4.76 (d, 1.6)	1.50 (3H, overlapped)	1.60 (3H, s)
OAc	1.95 (3H, s)	1.95 (3H, s)	1.95 (3H, s)		
1'	4.25 (2H, q, 7.1)	4.24 (2H, q, 7.1)	4.25 (2H, q, 7.1)		
2'	1.33 (3H, t, 7.1)	1.32 (3H, t, 7.1)	1.32 (3H, t, 7.1)		

Given the acetoxy group is likely to be attached to C-8 or C-6, there were two possible structures for compounds 1 and 2, namely the 8-OAc and 6-OAc isomers (Figure S18). DFT NMR calculation was performed on the two isomers to figure out the most possible structure. A conformational search was conducted using Conflex in a 5.0 kcal/mol energy window [14]. All conformers were reoptimized at the B3LYP/6-31G(d) in vacuo, and their  $^1\text{H}$  and  $^{13}\text{C}$  NMR chemical shifts were calculated at the level of mPW1PW91/6-311G(d,p) with the PCM solvent mode for chloroform [15]. The improved statistical method DP4+

was used to analyze the calculated data of two possible structures and the experimental data [16]. The results of compound **1** gave a 100.00% (all data) possibility for the 8-OAc isomer, and compound **2** gave 97.20% (all data) for the same isomer (Figures S19 and S20), suggesting both are 8-OAc derivatives.




**Figure 2.** Key  $^1\text{H}$ - $^1\text{H}$  COSY, HMBC, and NOESY correlations of compounds **1** and **2**.

The relative configurations of **1** and **2** were determined using the coupling constant and NOESY cross-peaks. The Z-form of C-3 and C-4 was revealed using the NOESY correlation of H-3/H<sub>3</sub>-15 in both **1** and **2**. The correlations of H<sub>3</sub>-14/H-8/H-6 were observed in the NOESY spectrum of **1** and **2**, which supported that H<sub>3</sub>-14, H-8, and H-6 were on the same face and in  $\beta$ -orientation. The coupling constant of  $J_{6-7}$  (10.4 Hz for **1**, 10.5 Hz for **2**) indicated that these two protons in both compounds were in a trans form. The correlation of H-1/H-5 and H-5/H-7 was observed for **1**, suggesting that H-1, H-5, and H-7 were on the same face and in  $\alpha$ -orientation. The correlations of H-5/H-7 and H<sub>3</sub>-14/H-1 were observed for **2**, suggesting that H-5 and H-7 were  $\alpha$ -orientated, while H-1 was  $\beta$ -orientated (Figure 2). Thus, compound **2** was proposed as a C-1 epimer of **1**. Therefore, the full structures of compounds **1** and **2** were established as shown and named divaricanolides A and B.

Compound **3** was obtained as a colorless oil. Its molecular formula  $\text{C}_{19}\text{H}_{28}\text{O}_6$  was deduced from the HR-ESIMS data, indicative of six indices of hydrogen deficiency. However, in the  $^{13}\text{C}$  NMR and DEPT spectra, only 18 carbon resonances were well resolved. After a detailed analysis of its HSQC and HMBC data, two methine carbon signals ( $\delta_{\text{C}}$  54.80;  $\delta_{\text{H}}$  2.62, 1.83) were found to have overlapped.


A comparison of its NMR data (Tables 1 and 2) with those of **1** showed that they possessed the same skeleton, having an acetoxy ( $\delta_{\text{H}}$  1.95;  $\delta_{\text{C}}$  170.3, 21.2) located at C-8, with an ethyl ester group located at C-13. The diagnostic signals for a terminal double bond ( $\delta_{\text{H}}$  5.03, 4.76;  $\delta_{\text{C}}$  109.1, 144.6) were observed for **3**, which were located at C-4 and C-15 using HMBC correlation (Figure 3) from H<sub>2</sub>-15 ( $\delta_{\text{H}}$  5.03 and 4.76) to C-3 ( $\delta_{\text{C}}$  34.9), C-4 ( $\delta_{\text{C}}$  144.6), and C-5 ( $\delta_{\text{C}}$  54.8). Analysis of the coupling constants and NOESY data established the relative stereochemistry of **3**. The NOESY correlations of H<sub>3</sub>-14/H-6 and H<sub>3</sub>-14/H-8 supported  $\beta$ -orientations of Me-14, H-6, and H-8, and  $\alpha$ -orientations of the hydroxy group at C-6 and the acetoxy group at C-8. The coupling constant of  $J_{6-7}$  (10.4 Hz) indicated a trans form of H-6 and H-7. The  $\beta$ -orientations of H-5 and H-1 were proved using the NOE correlations H-1/H-5 and H-1/H-7 (Figure 3). Therefore, the structure of **3** was proposed and named divaricanolide C.

Compound **4**, an colorless oil, had a molecular formula of  $\text{C}_{15}\text{H}_{20}\text{O}_3$ , which was established based on the HR-ESIMS ion at  $m/z$  249.1507  $[\text{M} + \text{H}]^+$  (calcd. for  $\text{C}_{15}\text{H}_{21}\text{O}_3$ , 249.1491), suggesting the presence of six degrees of unsaturation. The IR showed absorption bands for hydroxy ( $3447\text{ cm}^{-1}$ ) and carbonyl groups ( $1763\text{ cm}^{-1}$ ). The  $^{13}\text{C}$  NMR spectrum of **4** (Table 1) displayed one carbonyl carbon at  $\delta_{\text{C}}$  170.6 and six olefinic carbons at  $\delta_{\text{C}}$  147.1, 139.6, 132.5, 127.2, 123.4, and 121.1. The  $^1\text{H}$  NMR spectrum (Table 2) exhibited two methyl groups at  $\delta_{\text{H}}$  1.39 (s) and 1.50 (overlapped) and five olefinic protons at  $\delta_{\text{H}}$  6.17 (d), 5.71 (d), 5.46 (d), 5.18 (dd), and 5.15 (dd). The above spectroscopic data accounted for seven degrees of unsaturation, and the remaining two degrees of unsaturation were represented by a bicyclic carbon skeleton in compound **4**.




**Figure 3.** Key  $^1\text{H}$ - $^1\text{H}$  COSY correlations and HMBC and NOESY correlations of compound 3.

In the  $^1\text{H}$ - $^1\text{H}$  COSY spectrum, two fragments were established from the correlations of H<sub>2</sub>-5/H-6/H-7/H-8/H-9 and H<sub>2</sub>-1/H<sub>2</sub>-2/H-3 (Figure 4). Further HMBC correlation (Figure 4) from H-3 ( $\delta_{\text{H}}$  5.18, dd) to C-4 ( $\delta_{\text{C}}$  127.2)/C-5 ( $\delta_{\text{C}}$  45.4)/C-15(17.8) and from H<sub>3</sub>-14 ( $\delta_{\text{H}}$  1.39, s) to C-1 ( $\delta_{\text{C}}$  41.2)/C-9( $\delta_{\text{C}}$  147.1)/C-10 ( $\delta_{\text{C}}$  73.0) indicated the occurrence of a 10-membered ring with two methyl groups located at C-4 and C-10, respectively, and a hydroxy group at C-10. The presence of a fused unsaturated lactone ring at C-6 and C-7 was established using the HMBC correlations from H<sub>2</sub>-13( $\delta_{\text{H}}$  6.17, d; 5.46, d) to C-7 ( $\delta_{\text{C}}$  55.8), C-11 ( $\delta_{\text{C}}$  139.6), and C-12 ( $\delta_{\text{C}}$  170.6). Consequently, compound 4 was elucidated as a germacrane-type sesquiterpene.



**Figure 4.** Key  $^1\text{H}$ - $^1\text{H}$  COSY and HMBC correlations of compounds 4–9.

The NOESY correlations between H-3/H-5 and the coupling constant of  $J_{8-9}$  (16.1 Hz) inferred *E*-geometry for both C-3/C-4 and C-8/C-9 double bonds (Figure 5). Due to the fact that the  $\alpha$ -orientation of H-7 was reported for the majority of the naturally occurring germacrane-type sesquiterpenes, H-7 in compound 4 was tentatively defined as  $\alpha$ -orientation. The coupling constant of  $J_{6-7}$  (9.8 Hz) indicated that these two protons were in a *trans* form; namely, H-6 was  $\beta$ -orientated. The relative configuration of the OH-10 remained unclear. To further elucidate the relative configuration, the same DFT NMR calculation method used to describe compounds 1 and 2 was performed on two possible isomers with *rel*-(6*R*,7*S*,10*R*) and *rel*-(6*R*,7*S*,10*S*) configurations (Figure S37). The DP4+ statistical analysis showed a 100% DP4+ probability (all data) for the *rel*-(6*R*,7*S*,10*S*) isomer (Figure S38). Therefore, the structure of 4 was proposed as shown and named divaricanolide D.



**Figure 5.** NOESY correlations (dashed arrow) of compounds 4–9.

Compound **5**, a colorless oil, had a molecular formula of  $C_{15}H_{22}O_3$  established using HR-ESIMS. Its NMR data (Tables 1 and 2) were similar to those of compound **4**, suggesting that **5** might be an analogue of **4**. A comparison of their  $^1H$  and  $^{13}C$  NMR data revealed that an additional methyl signal ( $\delta_C$  12.6 and  $\delta_H$  1.19) was observed in **5**, accompanied by the absence of an exocyclic double bond when compared with **4**. The position of the additional methyl group was designated as Me-13 using the  $^1H$ - $^1H$  COSY correlations (Figure 4) of H-7 ( $\delta_H$  2.62)/H-11 ( $\delta_H$  2.43)/H<sub>3</sub>-13 ( $\delta_H$  1.19).

The NOESY correlations between H<sub>2</sub>-2/H<sub>3</sub>-15 and the coupling constant of  $J_{8,9}$  (16.0 Hz) revealed *E*-geometry for both the C-3/C-4 and C-8/C-9 double bonds. The coupling constant of  $J_{6,7}$  (12.1 Hz) indicated that these two protons kept in a *trans* form. The correlation of H<sub>3</sub>-13/H-7 and H-11/H-6 was observed in the NOESY spectrum, which supported that H<sub>3</sub>-13, and H-7 were in  $\alpha$ -orientation, while H-6 and H-11 were in  $\beta$ -orientation (Figure 5). Similar to compound **4**, the relative configuration of the hydroxyl group at C-10 was unclear. The same DFT NMR calculation was performed on two possible isomers, *rel*-(6*R*,7*S*,10*R*,11*S*)-**5** and (6*R*,7*S*,10*S*,11*S*)-**5** (Figure S47). The DP4+ analysis result provided a 100% probability (all data) for the (6*R*,7*S*,10*S*,11*S*)-**5** (Figure S48). Accordingly, the full structure of **5** was proposed and named divaricanolide E.

Compound **6**, a colorless oil, had a molecular formula of  $C_{15}H_{24}O_2$  established using HR-ESIMS, implying four degrees of unsaturation. Analysis of the  $^1H$  and  $^{13}C$  NMR data of **6** (Tables 1 and 3) revealed the existence of three double bonds, including one trisubstituted [ $\delta_C$  128.4,  $\delta_H$  5.25 (d);  $\delta_C$  136.0], two exocyclic [ $\delta_C$  113.0,  $\delta_H$  5.17 (s), 5.01 (s);  $\delta_C$  150.0;  $\delta_C$  110.5,  $\delta_H$  4.89 (s), 4.64 (s);  $\delta_C$  147.1], and two oxymethines [ $\delta_C$  74.6,  $\delta_H$  4.10 (dd);  $\delta_C$  67.7,  $\delta_H$  4.91 (dd)]. The remaining seven carbons were assigned to two methyls, four methylenes, and one methine. With one remaining unsaturation degree, **6** should be monocyclic.

The  $^1H$ - $^1H$  COSY spectrum of compound **6** proved to be very informative, as only two spin systems were detected, H-1/H<sub>2</sub>-2/H-3 and H-5/H<sub>2</sub>-6/H-7/H<sub>2</sub>-8/H-9 (Figure 4). The HMBC correlations from H<sub>2</sub>-15 ( $\delta_H$  5.17, 5.07) to C-3 ( $\delta_C$  22.7), C-4 ( $\delta_C$  150.0), and C-5 ( $\delta_C$  74.6) and H<sub>3</sub>-14 (1.74) to C-1 (67.7), C-9 (128.4), and C-10 (136.0) eventually merged two fragments into a 10-membered carbocycle typical of the germacranes skeleton, with two hydroxy groups located at C-1 and C-5, respectively (Figure 4). The 2-methyl-1-ene isopropyl group was placed at C-7 using the HMBC correlations from H<sub>3</sub>-12 ( $\delta_H$  1.85) to C-7 ( $\delta_C$  42.2), C-11 ( $\delta_C$  147.1), and C-13 ( $\delta_C$  110.5).

**Table 3.**  $^1\text{H}$  NMR data of compounds 6–9 ( $\delta$  in ppm,  $J$  in Hz, measured in  $\text{CDCl}_3$ ).

No.	6	7	8	9
1	4.91 (dd, 11.5, 5.3)	4.10 (dd, 7.9, 3.3)	4.11 (dd, 7.8, 3.2)	1.73–1.67 (m) 1.66 (ddd, 10.8, 5.3, 2.9)
2	2.16 (m) 1.81–1.75 (m)	1.91 (m) 1.78 (overlapped)	1.91 (dd, 7.5, 3.2) 1.80–1.76 (m)	2.06 (2H, m)
3	2.09 (m) 1.90 (ddd, 17.3, 13.6, 4.0)	1.69 (overlapped) 1.59 (ddd, 12.0, 7.7, 3.8)	1.60 (m) 1.57 (m)	4.47 (dd, 4.8, 2.3)
5	4.10 (dd, 11.0, 3.1)	5.51 (d, 16.0)	5.51 (d, 16.0)	2.97 (br s) 2.51 (dd, 12.8, 10.8)
6	2.04 (ddd, 14.3, 11.0, 3.3) 1.74 (m)	5.10 (dd, 16.0, 10.1)	5.11 (dd, 16.0, 10.1)	4.16 (ddd, 10.8, 9.2, 1.7)
7	2.26 (m)	2.59 (ddd, 11.8, 10.1, 5.0)	2.60 (ddd, 11.3, 10.1, 5.0)	3.59 (dd, 9.2, 8.9)
8	2.66 (ddd, 12.8, 12.6, 11.8) 1.83 (overlap)	1.96 (m) 1.80 (m)	2.00–1.93 (m) 1.84–1.80 (m)	5.32 (dd, 8.9, 2.2)
9	5.25 (d, 11.8)	2.38–2.28 (m) 1.70 (overlapped)	2.34 (m) 1.70 (overlapped)	3.00 (d, 2.2)
11				
12	1.85 (3H, s)	1.72 (3H, s)	1.73 (3H, s)	
13	4.89 (s) 4.64 (s)	4.72 (2H, s)	4.73 (2H, s)	6.18 (d, 3.2) 5.40 (d, 3.2)
14	1.71 (3H, s)	5.16 (s) 4.99 (s)	5.00 (d, 1.9) 5.17 (d, 1.9)	1.23 (3H, s)
15	5.17 (s) 5.01 (s)	1.30 (3H, s)	1.31 (3H, s)	5.39 (d, 2.0) 5.16 (d, 2.0)
OAc				2.21 (3H, s)

The NOESY correlations between H<sub>3</sub>-14/H-9 inferred *Z*-geometry for the C-9/C-10 double bond (Figure 5). Same as compound 4, the relative configuration of H-7 was tentatively defined as  $\alpha$ -orientation. Thus, the relative configurations of H-1 and H-5 still remained unclear. Then, DFT NMR calculation was performed on four possible isomers, with relative configurations of *rel*-(1*R*,5*R*,7*R*), *rel*-(1*S*,5*R*,7*R*), *rel*-(1*S*,5*R*,7*R*), and *rel*-(1*S*,5*S*,7*R*) (Figure S57). The DP4+ probability finally supported the *rel*-(1*S*,5*S*,7*R*) configuration with a 100% possibility for all data (Figure S58). Thus, the structure of 6 was proposed and named divaricanolide F.

Compound 7, a colorless oil, was given a molecular formula of C<sub>15</sub>H<sub>24</sub>O<sub>2</sub> using HR-ESIMS, corresponding to four degrees of unsaturation. Its NMR data (Tables 1 and 3) were similar to those of compound 6 except that one disubstituted double bond [ $\delta_{\text{C}}$  138.0,  $\delta_{\text{H}}$  5.51(d);  $\delta_{\text{C}}$  130.9,  $\delta_{\text{H}}$  5.10(dd)] and one oxygenated quaternary carbon ( $\delta_{\text{C}}$  74.0) were observed in 7, taking the place of the exocyclic double bond and the oxygenated methine in 6. In the  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound 7 (Figure 4), the correlations of H-5/H-6/H-7/H<sub>2</sub>-8/H<sub>2</sub>-9 proved the double bond located at C-5 and C-6. The hydroxyl group was placed at C-4, deduced from the HMBC correlations from H<sub>3</sub>-15 ( $\delta_{\text{H}}$  1.30) to C-3 ( $\delta_{\text{C}}$  38.0), C-4 ( $\delta_{\text{C}}$  74.0), and C-5 ( $\delta_{\text{C}}$  138.0) (Figure 4). The remaining exocyclic double bond was placed at C-10/C-14 using the HMBC correlations from H<sub>2</sub>-14 ( $\delta_{\text{H}}$  5.16, 4.99) to C-1 ( $\delta_{\text{C}}$  76.2), C-10 ( $\delta_{\text{C}}$  150.3), and C-9 ( $\delta_{\text{C}}$  30.5).

The NOESY correlations of H-5/H-7 and the coupling constant of  $J_{5,6}$  (16.0 Hz) all suggested *E*-geometry for the C-5/C-6 double bond (Figure 5 and Table 3). When H-7 was tentatively assigned as  $\alpha$ -orientated, the relative configurations of C-1 and C-4 remained unclear. Similarly, DFT NMR calculation was conducted on four possible isomers with relative configurations of *rel*-(1*R*,4*S*,7*R*), *rel*-(1*R*,4*R*,7*R*), *rel*-(1*S*,4*S*,7*R*), and *rel*-(1*S*,4*R*,7*R*)

(Figure S67). The DP4+ probability analysis gave a 100% possibility (all data) for the *rel*-(1*S*,4*R*,7*R*) configuration (Figure S68). Therefore, the structure of **7** was proposed and named divaricanolide G.

Compound **8** had a molecular formula of C<sub>15</sub>H<sub>22</sub>O established using HR-ESIMS, corresponding to five indices of hydrogen deficiency. The IR absorption at 3450 was assigned to the hydroxyl group. The <sup>13</sup>C NMR spectrum of **8** (Table 1) was very similar to that of **7**, suggesting they shared the same germacrane skeleton with similar functional groups. As compound **8** had one more degree of unsaturation than **7**, compound **8** might possess one more ring in the molecule. Given the existence of one nonproton-bearing oxygenated carbon at δ<sub>C</sub> 73.7 in **8** and less H<sub>2</sub>O in the molecular formula when compared with **7**, an oxygen bridge between C-1 and C-4 was constructed, which was consistent with the low-field resonance of H-1 (δ<sub>H</sub> 4.11, dd). Thus, the planar structure of **8** was established.

The C-5/C-6 double bond was given *E*-geometry using the NOESY correlations of H-5/H-7 and the coupling constant of *J*<sub>5-6</sub> (16.0 Hz) (Figure 5 and Table 3). The presence of the NOESY correlations of H-1/H<sub>a</sub>-3 and H<sub>a</sub>-3/H<sub>3</sub>-15 implied that H-1 and H<sub>3</sub>-15 were on the same face. However, the relationship between H-1/H<sub>3</sub>-15 and H-7 was uncertain. Similarly, DFT NMR calculation was performed on two possible isomers with relative configurations of *rel*-(1*R*,4*S*,7*R*) and *rel*-(1*S*,4*R*,7*R*) (Figure S77). The *rel*-(1*R*,4*S*,7*R*) configuration was finally designated for **8** using DP4+ probability with a 100% possibility for all data (Figure S78). Thus, the structure of **8** was proposed and named divaricanolide H.

Compound **9** was obtained as a colorless oil and possessed a molecular formula of C<sub>17</sub>H<sub>22</sub>O<sub>6</sub> using HR-ESIMS in coincidence with seven degrees of unsaturation. The <sup>1</sup>H and <sup>13</sup>C NMR (Tables 1 and 3) data of **9** exhibited characteristic signals for an acetoxy [δ<sub>H</sub> 2.21 (s, 3H); δ<sub>C</sub> 173.1, 20.6], two exocyclic methylenes [δ<sub>C</sub> 118.2, δ<sub>H</sub> 5.39 (d), 5.16 (d); δ<sub>C</sub> 144.5; δ<sub>C</sub> 120.6, δ<sub>H</sub> 6.18 (d), 5.40 (d); δ<sub>C</sub> 138.7], four oxygenated methines [δ<sub>C</sub> 81.8, δ<sub>H</sub> 4.16 (ddd); δ<sub>C</sub> 77.7, δ<sub>H</sub> 4.47 (d); δ<sub>C</sub> 77.1, δ<sub>H</sub> 3.00 (d); δ<sub>C</sub> 73.9, δ<sub>H</sub> 5.32 (dd)], and one quaternary carbon [δ<sub>C</sub> 69.8]. As the identified functional groups satisfied four degrees of unsaturation, the three left were indicative of a tricyclic ring system. The <sup>1</sup>H-<sup>1</sup>H COSY spectrum revealed two spin systems of H<sub>2</sub>-1/H<sub>2</sub>-2/H-3 and H<sub>2</sub>-5/H-6/H-7/H-8/H-9 (Figure 4). The γ-lactone ring was deduced to be fused to C-6 and C-7 from the key HMBC correlations from H<sub>2</sub>-13 (δ<sub>H</sub> 6.18, d; 5.40, d) to C-7 (δ<sub>C</sub> 49.7)/C-11(δ<sub>C</sub> 138.7)/C-12 (δ<sub>C</sub> 168.8). The HMBC correlations (Figure 4) from H<sub>3</sub>-14 (δ<sub>H</sub> 1.23, s) to C-1 (δ<sub>C</sub> 37.3) /C-9 (δ<sub>C</sub> 77.1)/C-10 (δ<sub>C</sub> 69.8) and from H<sub>2</sub>-15 (δ<sub>H</sub> 5.39, d; 5.16, d) to C-3 (δ<sub>C</sub> 77.7)/C-4 (δ<sub>C</sub> 144.5)/C-5 (δ<sub>C</sub> 41.9) further constructed a germacrane-type sesquiterpenoid lactone. A hydroxyl group was assigned to C-3 (δ<sub>C</sub> 77.7) according to its low-field chemical shift. An acetoxy group was fixed at C-8 based on the HMBC correlations from H-8 (δ<sub>H</sub> 5.32, dd) to a carboxylic carbon (δ<sub>C</sub> 173.0). Given the one degree of unsaturation left and the molecular formula, an epoxide ring might be present in **9**. The low-field resonances of H-9 (δ<sub>H</sub> 3.00) and C-10 (δ<sub>C</sub> 69.8) verified that the ether linkage was at C-9/C-10.

The NOESY correlations between H<sub>a</sub>-1/H<sub>3</sub>-14 and H<sub>b</sub>-1/H-9 revealed that H<sub>3</sub>-14 and H-9 were in a *trans* form (Figure 5). The coupling constant of *J*<sub>6-7</sub> (9.2 Hz) also indicated a *trans* form for H-6 and H-7 (Table 3). Still, there were no evidence to clarify the relative configurations of **9** due to the four isolated chiral centers, C-3, C-6/C-7, C-8, and C-9/C-10. Given the tentative α-orientation for H-7, the left three chiral centers generated eight possible isomers, *rel*-(3*S*,6*R*,7*S*,8*R*,9*S*,10*S*), *rel*-(3*R*,6*R*,7*S*,8*R*,9*S*,10*S*), *rel*-(3*S*,6*R*,7*S*,8*S*,9*S*,10*S*), *rel*-(3*R*,6*R*,7*S*,8*S*,9*S*,10*S*), *rel*-(3*S*,6*R*,7*S*,8*R*,9*R*,10*R*), *rel*-(3*R*,6*R*,7*S*,8*R*,9*R*,10*R*), *rel*-(3*S*,6*R*,7*S*,8*S*,9*R*,10*R*), and *rel*-(3*R*,6*R*,7*S*,8*S*,9*R*,10*R*) (Figure S87). DFT NMR calculation was conducted on the eight possible isomers, and the DP4+ probability analysis finally gave a 98.51% possibility (all data) to support the *rel*-(3*R*,6*R*,7*S*,8*R*,9*S*,10*S*) configuration (Figure S88). Thus, the structure of **9** was proposed and named divaricanolide I.


Apart from compounds **1**–**9**, 30 other known components were isolated and identified as austroyunnane H (**10**) [17], baynol C (**11**) [18], jatrophaeudesmene C (**12**) [19], dihydro-β-cyclopyrethrosin (**13**) [20], β-Cyclopyrethrosin (**14**) [21], yomogin (**15**) [22], (1*S*)-1β-Hydroxyeudes-m-4(14)-eno-13,6α-lactone (**16**) [23], reynosin (**17**) [24], 1β,8β-Dihydroxy-



reynosin (18) [25], artemorin (19) [26], 1-epi-Dihydrochrysanolide (20) [27], dihydrochrysanolide (21) [27], 5 $\beta$ ,6 $\alpha$ -Hydroxygermacra-1(10)*E*,4(15),11(13)-trien-12,8 $\alpha$ -olide (22) [28], tulirinol (23) [29], chamissarin (24) [19], 6 $\beta$ -Acetoxy-14-hydroxygermacra-4*E*,1(10)*E*,11(13)-trien-12,8 $\alpha$ -olide (25) [30], 6 $\beta$ -Acetoxy-3-formyl-3*Z*,9*E*,11(13)-trien-12,8 $\alpha$ -olide (26) [31], chrysanolide (27) [22], haagenolide (28) [32], 14-hydroxygermacra-4*E*,1(10)*E*,11(13)-trien-12,7 $\alpha$ -olide (29) [30], Chihuahuin (30) [29], austroliolide (31) [29], pyrethrosin (32) [29], 9 $\alpha$ ,10 $\beta$ -epoxi-8 $\alpha$ -Hydrox-germacra-3*Z*,11(13)-dien-6 $\alpha$ ,12-olide (33) [33], sinugibberodiol (34) [34], (3*R*,7*S*,9*S*)-3,9-Dihydroxygermacra-4(15),10(14),11(12)-triene (35) [35], (3*S*,7*S*,9*S*)-3,9-dihydroxygermacra-4(15),10(14),11(12)-triene (36) [34], germacra-1(10)*E*,4*E*-dien-2 $\beta$ ,6 $\beta$ -diol (37) [36], 4 $\beta$ ,5 $\alpha$ -Dihydroxycubenol (38) [37], and amarantholidoside III (39) [38] by comparing their spectroscopy data with those reported in the literature.

## 2.2. Anti-Inflammatory Activity Assay

Macrophage inflammation plays a vital role in metabolic diseases, neurodegenerative diseases, and cancers [39]. The current research suggests that inflammation involves a lot of pro-inflammatory cytokines. NO is an important inflammatory mediator in inflammation. Natural products have been considered important sources to identify anti-inflammatory agents [40]. Herein, eight new compounds (1–8) were tested for their inhibitory effects on NO production in LPS-stimulated RAW 264.7 macrophages for a preliminary evaluation of their anti-inflammatory activity (Figure 6). Firstly, the noncytotoxic concentrations of compounds 1–8 were evaluated using an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The MTT results showed that compounds 2, 5–6, and 8 did not show evident cytotoxicity up to 10  $\mu$ M (Figure 6B). Among these four compounds, only compounds 2 and 8 showed a significant inhibitory effect on the release of nitric oxide (NO) from RAW 264.7 cells (Figure 6A). Next, the IC<sub>50</sub> values of compounds 2 and 8 in inhibiting NO production were evaluated, which were  $5.35 \pm 0.75$  and  $7.68 \pm 0.54$   $\mu$ M, respectively.



**Figure 6.** Cytotoxic and NO production inhibitory effects of compounds isolated from *A. divaricate*. (A) Inhibitory rate of NO production. (B) The cell viability of RAW 264.7 cells treated with different compounds at concentration of 10  $\mu$ M. (C) Inhibitory rate of NO production for compounds 2 in LPS-induced RAW 264.7 cells. (D) Inhibitory rate of NO production for compounds 8 in LPS-induced RAW 264.7 cells. Data are shown as mean  $\pm$  SEM. #  $p < 0.001$  LPS vs. vehicle control. \*  $p < 0.01$  and \*\*  $p < 0.001$  compounds or dexamethasone vs. LPS.

### 3. Materials and Methods

#### 3.1. General Experimental Procedures

Optical rotations were recorded on a Rudolph Research Analytical Autopol VI 90079 polarimeter (Hackettstown, NJ, USA). ECD spectra were recorded using a J-815 CD spectropolarimeter (JASCO, Tokyo, Japan). IR spectra were recorded on a Nicolet FTIR IS5 spectrometer (Thermo Fisher, Waltham, MA, USA). HR-ESIMS spectra were measured on a Waters Synapt G2-Si Q-TOF instrument and Agilent G6520 Q-TOF. NMR spectra were obtained on a Bruker AVANCE III 500 or 600 MHz spectrometer (Bruker Biospin AG, Frankenstein, Switzerland). Analytical HPLC was performed on a Waters e2695 system equipped with a Waters 2998 photodiode array detector (PDA), a Waters 2424 evaporative light-scattering detector (ELSD), and a Waters 3100 MS detector. Preparative HPLC was run on a Waters system equipped with a Waters 2767 autosampler, a Waters 2545 pump, a Waters 2489 PDA, and an Acuity ELSD using a Waters Sunfire RP C18 column (5  $\mu$ m, 30  $\times$  150 mm, flow rate 30 mL/min). Sephadex LH-20 (Pharmacia Biotech AB, Uppsala, Sweden), MCI gel CHP20P (75–150  $\mu$ m, Mitsubishi Chemical Industries, Tokyo, Japan), ODS gel AAG12S50 (12 nm, S-50  $\mu$ m, YMC Co., Ltd., Tokyo, Japan), and silica gel (300–400 mesh, Qingdao Marine Chemical Inc., Qingdao, China) were used for column chromatography (CC). TLC analyses were performed on prefabricated GF<sub>254</sub> silica gel plates (Yantai Jiangyou silica gel development Co., Ltd., Yantai, China). All solvents were of analytical grade (Sinopharm Chemical Reagents Co., Ltd., Shanghai, China) for CC and of HPLC grade (Merck KGaA, Darmstadt, Germany) for HPLC and preparative HPLC.

#### 3.2. Plant Material

The whole plant of *A. divaricate* was collected from Ganzi Area of Sichuan Province, China, in August 2020. The plant material was authenticated by Mr. Zhang Jun from Kunming Zhifen Biotechnology Co., Ltd., Kunming, China. A voucher specimen (No. 2018090606) was deposited in the herbarium of Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

#### 3.3. Extraction and Isolation

The dried whole plant of *A. divaricate* (30.0 kg) was ground and extracted with 75 L 95% EtOH (7 days  $\times$  3) at room temperature. After removing the solvent, a crude residue (1.29 kg) was obtained, which was suspended in water and extracted successively with petroleum ether (PE), dichloromethane (DCM), and ethyl acetate (EA), affording fractions of PE (447.5 g), DCM (227.8 g), and EA (125.9 g), respectively. The DCM part was subjected to an AB-8 macroporous resin column eluted with aqueous EtOH in a step manner (20, 40, 60, 80, and 95%), affording five fractions: Frs. 1–5. Fr.2 (55.3 g) and Fr.3 (53.5 g) were combined and chromatographed over an MCI column eluted with aqueous MeOH (20, 30, 40, 50, 60, 70, 80, and 90%) to give Frs. 2A–2K. Fr. 2G (15.6 g) was subjected to an ODS gel column eluted with gradient elution of aqueous MeOH (30, 40, 50, 60, 70, and 80%) to afford subfractions of Frs. 2G1–2G10. Fr. 2G4 (4.0 g) was subjected to column chromatograph over Sephadex LH-20 gel (MeOH) to provide Frs. 2G4A–2G4F. Fr. 2G4B was subjected to silica gel CC (300–400 mesh) with gradient elution of DCM/MeOH (70:1–15:1) and then purified by preparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (0–35 min, from 21% to 41%) to give compound 3 (3.7 mg). Fr. 2G4C was separated using silica gel CC (300–400 mesh) with gradient elution of PE/acetone (15:1–2:1) and then preparative HPLC (19% to 39% CH<sub>3</sub>CN in H<sub>2</sub>O, 35 min) to yield compound 1 (1.8 mg) and compound 2 (2.5 mg). Fr. 2G6 (680.0 mg) was chromatographed over silica gel eluted with DCM-MeOH (40:1–20:1) and refined further using preparative HPLC (25–45% CH<sub>3</sub>CN in H<sub>2</sub>O, 35 min) to obtain compound 5 (18.1 mg). Fr. 2G7 (2.1 g) was subjected to CC over Sephadex LH-20 gel (MeOH) to afford Frs. 2G7A–2G7D. Fr. 2G7B was separated using CC over silica gel (300–400 mesh) with a gradient of DCM-EA (8:1–1:1) and then preparative HPLC (15–35% CH<sub>3</sub>CN in H<sub>2</sub>O, 35 min) to yield compound 8 (3.4 mg). Fr. 2G7C was separated using CC over silica gel (300–400 mesh) using a gradient of DCM-MEOH (40:1–20:1) and then preparative HPLC

(18–38% CH<sub>3</sub>CN in H<sub>2</sub>O, 35 min) to yield compound **4** (2.0 mg). Fr. 2G7E was separated using CC over silica gel (300–400 mesh) with a gradient of PE–acetone (6:1–2:1) and then preparative HPLC (25–45% CH<sub>3</sub>CN in H<sub>2</sub>O, 35 min) to yield compound **9** (0.8 mg). Frs. 2G8C and 2G8D were separated using a silica gel column (300–400 mesh) with a gradient of PE:acetone (10:1–2:1) to yield compounds **6** (3.9 mg) and **7** (7.8 mg), respectively.

Divaricanolide A (**1**): white powder;  $[\alpha]_D^{20} - 36$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 195 (+3.8) nm, 191.5 (−3.8) nm; IR(KBr)  $\nu_{\max}$  3440, 2921, 2852, 1715, 1626, 1440, 1371, 1324, 1240, 1176, 1022, 962 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR, see Tables 1 and 2; HR-ESIMS *m/z* 375.1858 [M + Na]<sup>+</sup> (calcd. for C<sub>19</sub>H<sub>28</sub>O<sub>6</sub>Na, 375.1784).

Divaricanolide B (**2**): white powder;  $[\alpha]_D^{20} + 60$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 208.8 (+1.7) nm, 203 (−3.1) nm, 201.5 (+6.0) nm, 197 (−5.4) nm, 195 (+2.1) nm, 191.5 (−4.9) nm, 190 (+4.6) nm; IR(KBr)  $\nu_{\max}$  3440, 2921, 2852, 1715, 1626, 1440, 1371, 1240, 1176, 1022 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; HR-ESIMS *m/z* 375.1874 [M + Na]<sup>+</sup> (calcd. for C<sub>19</sub>H<sub>28</sub>O<sub>6</sub>Na, 375.1784).

Divaricanolide C (**3**): colorless oil;  $[\alpha]_D^{20} - 48$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 192 (−12.2) nm; IR(KBr)  $\nu_{\max}$  3421, 2924, 2852, 1663, 1432, 1382, 1213, 1116, 1060 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; HR-ESIMS *m/z* 375.1858 [M + Na]<sup>+</sup> (calcd. for C<sub>19</sub>H<sub>28</sub>O<sub>6</sub>Na, 375.1784).

Divaricanolide D (**4**): colorless oil;  $[\alpha]_D^{20} - 28$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 203.5 (−12.2) nm; IR(KBr)  $\nu_{\max}$  3447, 2920, 1763, 1384, 1144 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; HR-ESIMS *m/z* 249.1507 [M + H]<sup>+</sup> (calcd. for C<sub>15</sub>H<sub>21</sub>O<sub>4</sub>, 249.1491).

Divaricanolide E (**5**): colorless oil;  $[\alpha]_D^{20} - 88$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 228.5 (−9.4) nm, 195.5 (+0.6) nm; IR(KBr)  $\nu_{\max}$  3447, 2924, 1773, 1383, 1185, 1109, 994 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2; HR-ESIMS *m/z* 273.1463 [M + Na]<sup>+</sup> (calcd. for C<sub>15</sub>H<sub>22</sub>O<sub>3</sub>Na, 273.1464).

Divaricanolide F (**6**): colorless oil;  $[\alpha]_D^{20} + 68$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 197 (−8.2) nm; IR(KBr)  $\nu_{\max}$  3355, 2927, 1642, 1449, 1376, 1015, 889 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 3; HR-ESIMS *m/z* 219.1744 [M + H − H<sub>2</sub>O]<sup>+</sup> (calcd. for C<sub>15</sub>H<sub>23</sub>O, 219.1749).

Divaricanolide G (**7**): colorless oil;  $[\alpha]_D^{20} + 68$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 200 (−19.8) nm, 220.5 (+1.5) nm; IR(KBr)  $\nu_{\max}$  3385, 3079, 2927, 1644, 1449, 1373, 1078, 1032, 977, 891 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 3; HR-ESIMS *m/z* 219.1744 [M + H − H<sub>2</sub>O]<sup>+</sup> (calcd. for C<sub>15</sub>H<sub>23</sub>O, 219.1749).

Divaricanolide H (**8**): colorless oil;  $[\alpha]_D^{20} - 91$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 191.5 (+10.8) nm, 198 (−14.8) nm; IR(KBr)  $\nu_{\max}$  3373, 2926, 2854, 1644, 1449, 1372, 1118, 1078, 1032, 977, 950, 891 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 3; HR-ESIMS *m/z* 219.1744 [M + H]<sup>+</sup> (calcd. for C<sub>15</sub>H<sub>23</sub>O, 219.1749).

Divaricanolide I (**9**): colorless oil;  $[\alpha]_D^{20} + 2.8$  (*c* 0.1, MeOH); ECD (MeOH) ( $\Delta\epsilon$ ) 213.5 (+4.6) nm, 194.5 (−4.2) nm; IR(KBr)  $\nu_{\max}$  2925, 1772, 1716, 1373, 1260 1145, 1077, 1041, 1026, 1002, 929, 959 cm<sup>−1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 3; HR-ESIMS *m/z* 323.1490 [M + H]<sup>+</sup> (calcd. for C<sub>17</sub>H<sub>23</sub>O<sub>6</sub>, 323.1489).

### 3.4. Computational Section

DFT NMR was performed using the Gaussian 16 program [14]. Conformational searching was conducted using Conflex 8.0 software with the MMFF force field within an energy window of 5.0 kcal/mol [14]. Conformers with the Boltzmann population above 0.1% were reoptimized at the B3LYP/6-311G(d) level in vacuo, and then their NMR data were calculated at the level of mPW1PW91/6-311G(d, p) with the PCM solvent mode for chloroform [15]. A possible configuration was specified using DP4+ probability [16]

### 3.5. Cell Culture

RAW 264.7 macrophages were purchased from American Type Cell Collection (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle Medium (DMEM) containing

10% fetal bovine serum (Gibco, Carlsbad, CA, USA) and 1% penicillin–streptomycin (Gibco, Carlsbad, CA, USA) in a humidified incubator with 5% CO<sub>2</sub> at 37 °C.

### 3.6. Cell Viability

The cell viability was evaluated using an MTT colorimetric assay [41]. RAW 264.7 macrophages were inoculated onto 96-well plates (at a concentration of  $1 \times 10^4$  cells per well) and allowed to adhere to the bottom of the plates and incubated in an incubator for 24 h. Then, the cells were treated with or without compounds at 10 µM and incubated for 18 h, and then the cells with DMEM medium containing 1 mg/mL MTT (Sigma-Aldrich, St. Louis, MO, USA) were incubated for 4 h. After that, DMSO was added to solubilize formazan precipitates. The optical density (OD) at 540 nm was measured using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). The calculation equation for relative cell viability is as follows: cell viability (%) =  $(A_s - A_0)/(A_c - A_0) \times 100\%$ , where  $A_s$ ,  $A_0$ , and  $A_c$  are the absorptions of test sample, blank control, and negative control (DMSO).

### 3.7. Measurement of Nitric Oxide (NO) Production

RAW 264.7 macrophages were inoculated onto 96-well plates (at a concentration of  $1 \times 10^4$  cells per well) and allowed to adhere to the bottom of the plates and incubated in an incubator for 24 h. The cells were then treated with different concentrations of compounds or vehicle (DMSO) for 1 h, followed by stimulation with 1 µg/mL LPS. DMSO was used as vehicle, with the final concentration of DMSO being maintained at 0.1% of all cultures. After 18 h incubation, the supernatant was collected to determine NO content using Griess reagent (Sigma, St. Louis, MO, USA), as described previously. The absorbance at 490 nm was measured using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA) [42].

### 3.8. Statistical Analysis

All data were expressed as mean  $\pm$  SEM based on at least three independent experiments and analyzed using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). One-way ANOVA was used for statistical comparison, and *p*-values less than 0.05 were considered statistically significant.

## 4. Conclusions

In summary, for the first time, a phytochemical investigation of *A. divaricate* was carried out, leading to the characterization of 39 sesquiterpenes, including 9 new ones. The structures of the isolated compounds involve germacrane-, eudesmane-, and bisabolane-type sesquiterpenes, which is consistent with the chemical constituents isolated from other *Artemisia* plants. The structure elucidation of the new compounds, especially the stereochemistry, were greatly supported by DFT NMR calculations. As a matter of fact, due to the existence of the flexible 10-membered ring of the germacrane-type sesquiterpenes, the NOESY correlations could not be used to convince the relative configurations. DFT NMR calculation could provide a powerful tool to figure out the relative configuration. Given the biogenetic relationship, absolute configuration could be further proposed. In the anti-inflammatory activity assay, compounds 2 and 8 showed a significant inhibitory effect on NO production in LPS-stimulated RAW 264.7 macrophages, with IC<sub>50</sub> values of  $5.35 \pm 0.75$  and  $7.68 \pm 0.54$  µM, respectively. Our findings provide the first understanding of the chemical constituents of the medicinal plant *A. divaricate* and enrich the structural diversity of the sesquiterpenes of the *Artemisia* plants.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules28104254/s1>, Structures of known compounds 10–38; 1D and 2D NMR data, IR spectra, and HRESIMS spectra of new compounds (1–9); structures of possible isomers of compounds 1, 2, and 4–9; DP4+ probability statistics of compounds 1, 2, and 4–9.

**Author Contributions:** Conceptualization, C.T. and Y.Y.; funding acquisition, Y.Y.; investigation, S.Y., Z.F. and C.T.; methodology, C.K.; project administration, C.T.; software, S.Y. and Z.F.; supervision, Y.Y.; validation, C.K., Z.F. and C.T.; writing—original draft, S.Y.; writing—review and editing, C.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Science and Technology Commission of Shanghai Municipality (20430780300) and the National Natural Science Foundation of China (21920102003). Z.L. Feng wanted to thank the Shanghai Pujiang Program (22PJ102).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data generated or analyzed during this study are included in this published article.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Samples of the compounds 1–9 are available from the authors.

## References

1. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. *J. Nat. Prod.* **2020**, *83*, 770–803. [[CrossRef](#)] [[PubMed](#)]
2. Ivanescu, B.; Miron, A.; Corciova, A. Sesquiterpene Lactones from *Artemisia* Genus: Biological Activities and Methods of Analysis. *J. Anal. Methods Chem.* **2015**, *2015*, 1–21. [[CrossRef](#)] [[PubMed](#)]
3. Martínez, M.J.A.; Olmo, L.; Ticona, L.A.; Benito, P.B. The *Artemisia* L. Genus: A Review of Bioactive Sesquiterpene Lactones. *Stud. Nat. Prod. Chem.* **2012**, *37*, 43–65.
4. Schmidt, T.J.; Khalid, S.A.; Romanha, A.J.; Alves, T.M.A.; Biavatti, M.W.; Brun, R.; Da, C.F.B.; De Castro, S.L.; Ferreira, V.F.; De Lacerda, M.V.G.; et al. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases—Part I. *Curr. Med. Chem.* **2012**, *19*, 2128–2175. [[CrossRef](#)] [[PubMed](#)]
5. Ke, Z.; Chen, X.Q.; Zheng, M.B.; Jian, Y.; Tang, P.F. Cytotoxic sesquiterpene lactones from *Artemisia myriantha*. *Phytochem. Lett.* **2020**, *37*, 33–36.
6. Shu, W.; Jian, S.; Ke, Z.; Chen, X.Q.; Zheng, M.B.; Jian, Y.; Tang, P.F. Sesquiterpenes from *Artemisia argyi*: Absolute Configurations and Biological Activities. *Eur. J. Org. Chem.* **2014**, *5*, 973–983.
7. Reinhardt, J.K.; Klemm, A.M.; Danton, O.; De Mieri, M.; Smieško, M.; Huber, R.; Bürgi, T.; Gründemann, C.; Hamburger, M. Sesquiterpene Lactones from *Artemisia argyi*: Absolute Configuration and Immunosuppressant Activity. *J. Nat. Prod.* **2019**, *82*, 1424–1433. [[CrossRef](#)]
8. Bai, M.; Chen, J.; Xu, W.; Dong, S.; Liu, Q.; Lin, B.; Huang, X.; Yao, G.; Song, S. Elephantopinolide A-P, germacrane-type sesquiterpene lactones from *Elephantopus scaber* induce apoptosis, autophagy and G2/M phase arrest in hepatocellular carcinoma cells. *Eur. J. Med. Chem.* **2020**, *198*, 112362–112375. [[CrossRef](#)]
9. Xu, W.; Bai, M.; Liu, D.; Qin, S.; Lv, T.; Li, Q.; Lin, B.; Song, S.; Huang, X. MS/MS-based molecular networking accelerated discovery of germacrane-type sesquiterpene lactones from *Elephantopus scaber* L. *Phytochemistry* **2022**, *198*, 113136–113146. [[CrossRef](#)]
10. Perveen, S.; Alqahtani, J.; Orfali, R.; Aati, H.Y.; Al-Taweel, A.M.; Ibrahim, T.A.; Khan, A.; Yusufoglu, H.S.; Abdel-Kader, M.S.; Tagliatalata-Scafati, O. Antibacterial and Antifungal Sesquiterpenoids from Aerial Parts of *Anvillea garcinii*. *Molecules* **2020**, *25*, 1730. [[CrossRef](#)]
11. Zhu, N.; Tang, C.; Xu, C.; Ke, C.; Lin, G.; Jenis, J.; Yao, S.; Liu, H.; Ye, Y. Cytotoxic Germacrane-Type Sesquiterpene Lactones from the Whole Plant of *Carpesium lipskyi*. *J. Nat. Prod.* **2019**, *82*, 919–927. [[CrossRef](#)] [[PubMed](#)]
12. Yan, C.; Long, Q.; Zhang, Y.; Babu, G.; Krishnapriya, M.V.; Qiu, J.; Song, J.; Rao, Q.; Yi, P.; Sun, M.; et al. Germacranolide sesquiterpenes from *Carpesium cernuum* and their anti-leukemia activity. *Chin. J. Nat. Med.* **2021**, *19*, 528–535. [[CrossRef](#)] [[PubMed](#)]
13. Wu, Z.Y.; Raven, P.H.; Hong, D.Y. *Flora of China*; Science Press (Beijing) & Missouri Botanical Garden Press: Beijing, China, 2011.
14. *Gaussian 09*; Computer Program. Gaussian, Inc.: Wallingford, CT, USA, 2013.
15. *CONFLEX 8*; Computer Program. CONFLEX Corporation: Tokyo, Japan, 2017.
16. Grimblat, N.; Zanardi, M.M.; Sarotti, A.M. Beyond DP4: An Improved Probability for the Stereochemical Assignment of Isomeric Compounds using Quantum Chemical Calculations of NMR Shifts. *J. Org. Chem.* **2015**, *80*, 12526–12534. [[CrossRef](#)] [[PubMed](#)]
17. Chi, J.; Li, B.; Dai, W.; Liu, L.; Zhang, M. Highly oxidized sesquiterpenes from *Artemisia austroyunnanensis*. *Fitoterapia* **2016**, *115*, 182–188. [[CrossRef](#)] [[PubMed](#)]
18. Lee, T.; Lee, S.; Kim, K.H.; Oh, K.; Shin, J.; Mar, W. Effects of magnolialide isolated from the leaves of *Laurus nobilis* L. (Lauraceae) on immunoglobulin E-mediated type I hypersensitivity in vitro. *J. Ethnopharmacol.* **2013**, *149*, 550–556. [[CrossRef](#)] [[PubMed](#)]
19. Yang, Y.; Liu, J.; Li, Z.; Li, Y.; Qiu, M. New eudesmenic acid methyl esters from the seed oil of *Jatropha curcas*. *Fitoterapia* **2013**, *89*, 278–284. [[CrossRef](#)] [[PubMed](#)]
20. Galal, A.M. Microbial Transformation of Pyrethrosin. *J. Nat. Prod.* **2001**, *64*, 1098–1099. [[CrossRef](#)]

21. Zhen, X.; Wang, X.; Wang, C.P.; Li, G.H. Chemical constituents and biological activities of *Pyrethrum cinerariifolium*. *Guizhou* **2016**, *36*, 747–751.
22. Xue, G.M.; Zhao, C.G.; Xue, J.F.; Xing, G.F.; Zhao, Z.Z.; Du, K.; Si, Y.Y.; Sun, Y.J.; Feng, W.S. Chemical constituents from seeds of *Artemisia argyi*. *Chin. Tradit. Herbal Drugs* **2022**, *53*, 2605–2611.
23. Zhu, Y.; Zhang, L.; Zhao, Y.; Huang, G. Unusual sesquiterpene lactones with a new carbon skeleton and new acetylenes from *Ajania przewalskii*. *Food Chem.* **2010**, *118*, 228–238. [[CrossRef](#)]
24. Yang, H.; Xie, J.L.; Sun, H.D. Study on chemical constituents from the roots of *Saussurea lappa*. *Chin. J. Chin. Mater. Med.* **1997**, *12*, 94–98.
25. Konstantinopoulou, M.; Karioti, A.; Skaltsas, S.; Skaltsa, H. Sesquiterpene Lactones from *Anthemisa litissima* and Their Anti-*Helicobacter pylori* Activity. *J. Nat. Prod.* **2003**, *66*, 699–702. [[CrossRef](#)] [[PubMed](#)]
26. Bethencourt-Estrella, C.J.; Nocchi, N.; López-Arencibia, A.; San Nicolás-Hernández, D.; Souto, M.L.; Suárez-Gómez, B.; Díaz-Marrero, A.R.; Fernández, J.J.; Lorenzo-Morales, J.; Piñero, J.E. Antikinetoplastid Activity of Sesquiterpenes Isolated from the *Zoanthid Palythoa aff. clavata*. *Pharmaceuticals* **2021**, *14*, 1095. [[CrossRef](#)] [[PubMed](#)]
27. Lee, K.D.; Yang, M.S.; Ha, T.J.; Park, K.M.; Park, K.H. Isolation and Identification of Dihydrochrysanolide and Its 1-Epimer from *Chrysanthemum coro-narium* L. *Biosci. Biotechnol. Biochem.* **2002**, *4*, 862–865. [[CrossRef](#)] [[PubMed](#)]
28. Izbosarov, M.B.; Abduazimov, B.K.; Yusupova, I.M.; Tashkhodzhaev, B.; Abdullaev, A.D.V.D. Germacranolide from *Tanacetopsis mucronata*. *Chem. Nat. Commun.* **1998**, *34*, 456–461. [[CrossRef](#)]
29. Fraga, B.M.; Terrero, D.; Cabrera, I.; Reina, M. Studies on the sesquiterpene lactones from *Laurus novocanariensis* lead to the clarification of the structures of 1-epi-tatridin B and its epimer tatridin B. *Phytochemistry* **2018**, *153*, 48–52. [[CrossRef](#)]
30. Bai, L.; Liu, Q.; Cen, Y.; Huang, J.; Zhang, X.; Guo, S.; Zhang, L.; Guo, T.; Ho, C.T.; Bai, N. A new sesquiterpene lactone glucoside and other constituents from *Inula salsoloides* with insecticidal activities on striped flea beetle (*Phyllotreta striolata* Fabricius). *Nat. Prod. Res.* **2018**, *32*, 552–557. [[CrossRef](#)]
31. Ito, M.H.A.K. Regio- and Stereo-specific Allylic Oxidation of Germacrane-type Sesquiterpene Lactones with Selenium Dioxide and t-Butyl Hydroperoxide. *J. Chem. Soc. Chem. Commun.* **1981**, *10*, 483–485.
32. Cimmino, A.; Roschetto, E.; Masi, M.; Tuzi, A.; Radjai, I.; Gahdab, C.; Paolillo, R.; Guarino, A.; Catania, M.R.; Evidente, A. Sesquiterpene Lactones from *Cotula cinerea* with Antibiotic Activity against Clinical Isolates of *Enterococcus faecalis*. *Antibiotics* **2021**, *10*, 819. [[CrossRef](#)]
33. Triana, J.; Eiroa, J.L.; Morales, M.; Perez, F.J.; Brouard, I.; Marrero, M.T.; Estevez, S.; Quintana, J.; Estevez, F.; Castillo, Q.A.; et al. A chemo-taxonomic study of endemic species of genus *Tanacetum* from the Canary Islands. *Phytochemistry* **2013**, *92*, 87–104. [[CrossRef](#)]
34. Zhao, M.; Zhang, X.; Wang, Y.; Huang, M.; Duan, J.A.; Godecke, T.; Szymulanska-Ramamurthy, K.M.; Yin, Z.; Che, C.T. Germacrane and m-menthane from *Illicium lanceolatum*. *Molecules* **2014**, *19*, 4326–4337. [[CrossRef](#)] [[PubMed](#)]
35. Triana, J.; Lopez, M.; Rico, M.; Gonzalez-Platas, J.; Quintana, J.; Estevez, F.; Leon, F.; Bermejo, J. Sesquiterpenoid derivatives from *Gonospermum elegans* and their cytotoxic activity for HL-60 human promyelocytic cells. *J. Nat. Prod.* **2003**, *66*, 943–948. [[CrossRef](#)] [[PubMed](#)]
36. Sanz, J.F.; García-Sarrión, A.; Marco, J.A. Germacrane derivatives from *Santolina chamaecyparissus*. *Phytochemistry* **1991**, *30*, 9–10. [[CrossRef](#)]
37. Liu, S.; Zhang, J.; He, F.; Fu, W.; Tang, B.; Bin, Y.; Fang, M.; Wu, Z.; Qiu, Y. Anti-inflammatory sesquiterpenoids from the heartwood of *Juniperus formosana* Hayata. *Fitoterapia* **2022**, *157*, 105105–105123. [[CrossRef](#)]
38. D’Abrosca, B.; De Maria, P.; DellaGreca, M.; Fiorentino, A.; Golino, A.; Izzo, A.; Monaco, P. Amarantholidols and amarantholidosides: New nerolidol derivatives from the weed *Amaranthus retroflexus*. *Tetrahedron* **2006**, *62*, 640–646. [[CrossRef](#)]
39. Watanabe, S.; Alexander, M.; Misharin, A.V.; Budinger, G.R.S. The role of macrophages in the resolution of inflammation. *J. Clin. Investig.* **2019**, *130*, 2619–2628. [[CrossRef](#)]
40. Li, D.; Zhang, T.; Lu, J.; Peng, C.; Lin, L. Natural constituents from food sources as therapeutic agents for obesity and metabolic diseases targeting adipose tissue inflammation. *Crit. Rev. Food Sci.* **2020**, *61*, 1947–1965. [[CrossRef](#)]
41. Feng, Z.; Zhang, L.; Zheng, Y.; Liu, Q.; Liu, J.; Feng, L.; Huang, L.; Zhang, Q.; Lu, J.; Lin, L. Norditerpenoids and Dinorditerpenoids from the Seeds of *Podocarpus nagi* as Cytotoxic Agents and Autophagy Inducers. *J. Nat. Prod.* **2017**, *80*, 2110–2117. [[CrossRef](#)]
42. Feng, Z.; Chen, J.; Feng, L.; Chen, C.; Ye, Y.; Lin, L. Polyisoprenylated benzophenone derivatives from *Garcinia cambogia* and their anti-inflammatory activities. *Food Funct.* **2021**, *12*, 6432–6441. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.